Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to establish the recommended dose/Maximum Tolerated Dose (MTD) of Tarceva in children as single agent and in combination with radiation therapy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

NCT00360854

Brain and Central Nervous System Tumors

UNKNOWN PHASE1

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

NCT00077454

Previously Treated Childhood Rhabdomyosarcoma Recurrent Childhood Brain Tumor Recurrent Childhood Cerebellar Astrocytoma +9 more

COMPLETED PHASE1

Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents

NCT01535183

Brain Tumor

UNKNOWN PHASE2

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

NCT01518413

Rhabdomyosarcoma and Other Soft Tissue Sarcomas Ewing's Sarcoma Family of Tumors Osteosarcoma +2 more

COMPLETED PHASE1

Irinotecan in Treating Children With Refractory Solid Tumors

NCT00004078

Childhood Central Nervous System Germ Cell Tumor Childhood Choroid Plexus Tumor Childhood Craniopharyngioma +18 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prognosis in relapsing malignant brain tumors is poor. Those in brain stem gliomas is dismal; median survival of these children does not exceed 9 months. Radiation therapy may result in early and transient amelioration of symptoms, but have not contributed to increase or prolong survival. Moreover, chemotherapy has not increased this outcome to date.Prados et al. reported encouraging results from a phase I study of TarcevaTM/OSI-774 alone or with temozolomide (TMZ) in patients with malignant gliomas. Of 25 evaluated patients, 6 experienced PR: 4 GBM (glioblastoma multiforme) and 1 grade 3 astrocytoma treated with TarcevaTM alone, 1 GBM treated with TarcevaTM/TMZ; 2 had minor responses, and 3 stable diseases. These results in malignant glioma and the lack of efficacy in brain stem glioma with current treatment suggests the evaluation of this new therapeutic agent in children with relapsed brain tumors and upfront at diagnosis in brain stem glioma in combination with radiation therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Brain Tumor Brain Stem Glioma,

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tarceva (Erlotinib Hydrochloride)

tablets of 25 mg, 100 mg and 150 mg 75 to 150 mg/m² Once daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed malignant brain tumor
* Disease must be considered refractory to first line or relapsing after conventional therapy and for which no effective conventional treatment exists.·
* Newly diagnosed, histologically proven brain stem glioma, except pilocytic astrocytomas.
* Age: 1 to ≤ 21 years of age at study entry
* Life expectancy: at least 8 weeks
* ECOG Performance status ≤ 1 or Lansky-Play Scale\>= 70%, and including children with motor paresis due to disease
* Measurable or evaluable disease
* No other serious concomitant illness
* No organ toxicity \> grade 2 NCI-CTC AE v3.0, except alopecia and neurological symptoms due to disease

Exclusion Criteria

* Patients with spontaneous intratumoral hemorrhage will not be included in the study, in exception of small post-biopsy hemorrhage due to biopsy procedure
* Pregnant and breast feeding woman
* Uncontrolled intercurrent illness or active infection
* Chemotherapy within 4 weeks prior to study medication (within 6 weeks, if the regimen contained a nitrosourea)
* Radiation therapy within 6 weeks prior to study medication
* Any clinical or non-clinical evidence of pulmonary dysfunction or pre-existing lung disease
* Severe cardiac pathology; history of myocardial infarction within the year prior to inclusion
* Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjögren syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions
* Treatment with Coumarin (warfarin)

Minimum Eligible Age

1 Year

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No